Lenalidomide

{
  "id": "MLC-T-ONC-004774",
  "term": "Lenalidomide",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug that is similar to thalidomide and is used alone or with other drugs to treat adults with certain types of follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, multiple myeloma, or anemia caused by certain types of myelodysplastic syndromes. It is also being studied in the treatment of other conditions and types of cancer. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow. Lenalidomide is a type of antiangiogenesis agent and a type of immunomodulating agent. Also called CC-5013 and Revlimid.",
    "A thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells."
  ],
  "synonyms": [
    "CC-5013",
    "Revlimid",
    "IMiD-1"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lenalidomide/"
}